This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the
efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy
in adult subjects with previously treated recurrent or metastatic cervical carcinoma.
1. Able to provide written and signed informed consent and any locally required
authorization obtained from the subject/legal representative.
2. Women aged ≥18 years at the time of study entry.
3. Subjects must have histologically or cytologically confirmed recurrent or metastatic
squamous carcinoma or adenosquamous carcinoma of the cervix, and meet the following
criteria: disease progression confirmed by radiologic imaging during or following
prior platinum based doublet chemotherapy, with or without bevacizumab for recurrent
or metastatic cervical cancer; No more than 2 prior systemic therapies in the
recurrent or metastatic setting.
4. Subjects must have measurable lesions according to RECIST v1.1. The presence of
measurable lesions must be confirmed by the IRRC. A previously irradiated lesion is
not considered measurable and cannot be selected as a target lesion.
5. Available archived tumor tissue sample - block or a minimum of 10 unstained slides of
formalin fixed paraffin embedded [FFPE] tissues - preferably from the most recent
biopsy of a tumor lesion collected either at the time of or after the diagnosis of
locally advanced, recurrent, and/or metastatic disease has been made.
6. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
7. Life expectancy ≥12 weeks.
8. Adequate organ function.
1. Concurrent enrollment in another clinical study, unless it is an observational
(noninterventional) clinical study or the follow-up period of an interventional study.
2. Histological types of cervical cancer other than squamous carcinoma and adeno-squamous
carcinoma (eg, adenocarcinoma, small cell carcinoma, clear cell carcinoma, sarcoma,
3. Prior malignancy active within the previous 2 years except for the tumor for which a
subject is enrolled in the study, and locally curable cancers that have been
apparently cured, such as basal cell skin cancer, or carcinoma in situ of the breast.
4. Brain/central nervous system (CNS) metastases.
5. Clinically significant hydronephrosis, as determined by the investigator, not
alleviated by nephrostomy or ureteral stent
6. Active infections (including tuberculosis) requiring systemic antibacterial,
antifungal, or antiviral therapy within 4 weeks prior to the first dose of
7. Known history of testing positive for human immunodeficiency virus (HIV) or known
active acquired immunodeficiency syndrome.
8. Known active hepatitis B or C infections (known positive hepatitis B surface antigen
[HBsAg] result or positive hepatitis C virus [HCV] antibody with detectable HCV
ribonucleic acid [RNA] results).
9. Active or prior documented autoimmune disease that may relapse.
10. History of interstitial lung disease or noninfectious pneumonitis, except for those
induced by radiation therapies.
11. Patients with clinically significant cardio-cerebrovascular disease.
12. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to
NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the eligibility criteria with
the exception of toxicities not considered a safety risk.
13. History of severe hypersensitivity reactions to other mAbs.
14. Prior allogeneic stem cell transplantation or organ transplantation.
15. Known allergy or reaction to any component of the AK104 formulation.
16. Receipt of the following treatments or procedures: anticancer small molecule targeted
agent within 2 weeks, radiation therapy within 2 weeks, other anticancer therapy
within 4 weeks, any major surgery within 4 weeks, any other investigational product or
procedure within 4 weeks, or agents with immunomodulatory effect within 2 weeks prior
to the first dose of investigational product.
17. Subjects with a condition requiring systemic treatment with either corticosteroids
(>10 mg daily doses of prednisone or equivalent) or other immunosuppressive
medications within 14 days prior to the first dose of investigational product.
18. Receipt of live attenuated vaccines within 30 days prior to the first dose of
19. Prior exposure to any experimental antitumor vaccines, or any agent targeting T-cell
costimulation or immune checkpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-PD-L2,
anti-CTLA-4, anti-CD137 or anti-OX40 antibody, etc).
20. Any condition that, in the opinion of the Investigator, would interfere with
evaluation of the investigational product or interpretation of subject safety or study